By Regulatory Approvals — Business Watch: Solstice, Element cancel deal; FDA approves daraxonrasib for pancreatic cancer C&EN
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 1, 2026.